1
|
Minich WB, Abel BS, Schwiebert C, Welsink T, Seemann P, Brown RJ, Schomburg L. A Novel In Vitro Assay Correlates Insulin Receptor Autoantibodies With Fasting Insulin in Type B Insulin Resistance. J Clin Endocrinol Metab 2023; 108:2324-2329. [PMID: 36869714 PMCID: PMC10438904 DOI: 10.1210/clinem/dgad125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 02/22/2023] [Accepted: 03/01/2023] [Indexed: 03/05/2023]
Abstract
CONTEXT Severe insulin resistance (IR) in the presence of insulin receptor autoantibodies (InsR-aAb) is known as type B insulin resistance (TBIR). Considerable progress in therapy has been achieved, but diagnosis and monitoring of InsR-aAb remains a challenge. OBJECTIVE This work aimed to establish a robust in vitro method for InsR-Ab quantification. METHODS Longitudinal serum samples from patients with TBIR at the National Institutes of Health were collected. A bridge-assay for InsR-aAb detection was established using recombinant human insulin receptor as bait and detector. Monoclonal antibodies served as positive controls for validation. RESULTS The novel assay proved sensitive, robust, and passed quality control. The measured InsR-aAb from TBIR patients was associated with disease severity, decreased on treatment, and inhibited insulin signaling in vitro. Titers of InsR-aAb correlated positively to fasting insulin in patients. CONCLUSION Quantification of InsR-aAb from serum samples via the novel in vitro assay enables identification of TBIR and monitoring of successful therapy.
Collapse
Affiliation(s)
- Waldemar B Minich
- Institute for Experimental Endocrinology, Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, D-10115, Berlin, Germany
| | - Brent S Abel
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
| | - Christian Schwiebert
- Institute for Experimental Endocrinology, Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, D-10115, Berlin, Germany
- selenOmed GmbH, D-10965, Berlin, Germany
| | - Tim Welsink
- Institute for Experimental Endocrinology, Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, D-10115, Berlin, Germany
- selenOmed GmbH, D-10965, Berlin, Germany
| | - Petra Seemann
- Institute for Experimental Endocrinology, Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, D-10115, Berlin, Germany
- InVivo BioTech Services GmbH, D-16761, Hennigsdorf, Germany
| | - Rebecca J Brown
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
| | - Lutz Schomburg
- Institute for Experimental Endocrinology, Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, D-10115, Berlin, Germany
| |
Collapse
|
2
|
Schwiebert C, Kühnen P, Becker NP, Welsink T, Keller T, Minich WB, Wiegand S, Schomburg L. Antagonistic Autoantibodies to Insulin-Like Growth Factor-1 Receptor Associate with Poor Physical Strength. Int J Mol Sci 2020; 21:ijms21020463. [PMID: 31940750 PMCID: PMC7013472 DOI: 10.3390/ijms21020463] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 01/08/2020] [Accepted: 01/10/2020] [Indexed: 01/04/2023] Open
Abstract
Natural autoantibodies to the IGF1 receptor (IGF1R-aAb) have been described in relation to Graves' ophthalmopathy. Other physiological roles of natural IGF1R-aAb are not known. We hypothesized that IGF1R-aAb may be related to muscle development. Serum samples (n = 408) from young overweight subjects (n = 143) were collected during a lifestyle intervention study. Anthropometric parameters, along with leptin, IGF1 and IGF1R-aAb concentrations, were analyzed, and the subjects were categorized into positive or negative for IGF1R-aAb. Eleven out of 143 subjects (7.7%) were positive for IGF1R-aAb. Identified IGF1R-aAb were molecularly characterized and showed antagonistic activity in vitro impairing IGF1-mediated IGF1R activation. Mean body weight, height or age were similar between IGF1R-aAb-positive and -negative subjects, but IGF1 concentrations differed. Jumping ability, as well as right and left handgrip strengths, were lower in the IGF1R-aAb-positive as compared to the IGF1R-aAb-negative subjects. We conclude that natural IGF1R-aAb are detectable in apparently healthy subjects and are capable of antagonizing IGF1-dependent IGF1R activation. Moreover, the presence of IGF1R-aAb is associated with poor physical strength. Although the causality of this association is unclear, the data imply a potential influence of IGF1R autoimmunity on muscle development.
Collapse
Affiliation(s)
- Christian Schwiebert
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Peter Kühnen
- Department of Paediatric Endocrinology and Diabetology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (P.K.); (S.W.)
| | - Niels-Peter Becker
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Tim Welsink
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Theresa Keller
- Institute of Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Charitéplatz 1, D-10117 Berlin, Germany;
| | - Waldemar B. Minich
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Susanna Wiegand
- Department of Paediatric Endocrinology and Diabetology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (P.K.); (S.W.)
| | - Lutz Schomburg
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
- Correspondence: ; Tel.: +49-30-450-524289
| |
Collapse
|
3
|
Kühn-Heid ECD, Kühn EC, Ney J, Wendt S, Seelig J, Schwiebert C, Minich WB, Stoppe C, Schomburg L. Selenium-Binding Protein 1 Indicates Myocardial Stress and Risk for Adverse Outcome in Cardiac Surgery. Nutrients 2019; 11:nu11092005. [PMID: 31450690 PMCID: PMC6769850 DOI: 10.3390/nu11092005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 08/21/2019] [Accepted: 08/22/2019] [Indexed: 12/24/2022] Open
Abstract
Selenium-binding protein 1 (SELENBP1) is an intracellular protein that has been detected in the circulation in response to myocardial infarction. Hypoxia and cardiac surgery affect selenoprotein expression and selenium (Se) status. For this reason, we decided to analyze circulating SELENBP1 concentrations in patients (n = 75) necessitating cardioplegia and a cardiopulmonary bypass (CPB) during the course of the cardiac surgery. Serum samples were collected at seven time-points spanning the full surgical process. SELENBP1 was quantified by a highly sensitive newly developed immunological assay. Serum concentrations of SELENBP1 increased markedly during the intervention and showed a positive association with the duration of ischemia (ρ = 0.6, p < 0.0001). Elevated serum SELENBP1 concentrations at 1 h after arrival at the intensive care unit (post-surgery) were predictive to identify patients at risk of adverse outcome (death, bradycardia or cerebral ischemia, "endpoint 1"; OR 29.9, CI 3.3-268.8, p = 0.00027). Circulating SELENBP1 during intervention (2 min after reperfusion or 15 min after weaning from the CPB) correlated positively with an established marker of myocardial infarction (CK-MB) measured after the intervention (each with ρ = 0.5, p < 0.0001). We concluded that serum concentrations of SELENBP1 were strongly associated with cardiac arrest and the duration of myocardial ischemia already early during surgery, thereby constituting a novel and promising quantitative marker for myocardial hypoxia, with a high potential to improve diagnostics and prediction in combination with the established clinical parameters.
Collapse
Affiliation(s)
- Ellen C D Kühn-Heid
- Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-13353 Berlin, Germany
| | - Eike C Kühn
- Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-13353 Berlin, Germany
| | - Julia Ney
- Cardiovascular Critical Care & Anesthesia Research and Evaluation (3CARE), RWTH-Aachen University, D-52074 Aachen, Germany
| | - Sebastian Wendt
- Cardiovascular Critical Care & Anesthesia Research and Evaluation (3CARE), RWTH-Aachen University, D-52074 Aachen, Germany
- Department of Anesthesiology, Uniklinik RWTH-Aachen, D-52074 Aachen, Germany
| | - Julian Seelig
- Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-13353 Berlin, Germany
| | - Christian Schwiebert
- Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-13353 Berlin, Germany
| | - Waldemar B Minich
- Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-13353 Berlin, Germany
| | - Christian Stoppe
- Cardiovascular Critical Care & Anesthesia Research and Evaluation (3CARE), RWTH-Aachen University, D-52074 Aachen, Germany
| | - Lutz Schomburg
- Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-13353 Berlin, Germany.
| |
Collapse
|
4
|
Kühn EC, Slagman A, Kühn-Heid ECD, Seelig J, Schwiebert C, Minich WB, Stoppe C, Möckel M, Schomburg L. Circulating levels of selenium-binding protein 1 (SELENBP1) are associated with risk for major adverse cardiac events and death. J Trace Elem Med Biol 2019; 52:247-253. [PMID: 30732890 DOI: 10.1016/j.jtemb.2019.01.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 12/30/2018] [Accepted: 01/07/2019] [Indexed: 12/15/2022]
Abstract
OBJECTIVE Selenium-binding protein 1 (SELENBP1) is an intracellular protein with variable expression in response to cellular stress. As the selenium (Se) status is affected by inflammation and hypoxia, we hypothesized that SELENBP1 contributes to disease-specific Se metabolism. To test this hypothesis, a quantitative assay was developed and used to monitor SELENBP1 in patients with acute coronary syndrome (ACS). MATERIALS AND METHODS SELENBP1 was expressed, antibodies were generated and a luminometric immuno assay (LIA) was established and characterized. Serum samples were collected from controls (n = 37) and patients (n = 85) admitted to the Chest Pain Unit with suspected ACS. Blood samples were available from time of first medical contact in the ambulance, at admission to hospital, and after 2, 4, 6 and 12-36 h. RESULTS Circulating SELENBP1 was close to limit of detection in healthy controls and elevated in patients with suspected ACS. SELENBP1 was unrelated to other biomarkers of myocardial damage such as troponin T or aspartate aminotransferase. Serum SELENBP1 enabled a categorization of patients on first medical contact as either high-risk or low-risk for major adverse cardiac events (MACE) or death, when using 0.8 nmol/l as threshold. The odds-ratios (OR) for MACE and death were OR = 11 (95% CI: 2-49, p = 0.0022) and OR = 12 (2-74, p = 0.014), respectively. CONCLUSIONS Until now, SELENBP1 was mainly considered as an intracellular protein involved in Se metabolism and redox control. Our data indicate that SELENBP1 constitutes a circulating biomarker for cardiac events categorizing patients with suspected ACS at first medical contact into high-risk or low-risk for MACE and death, independent from and complimentary to current biomarkers.
Collapse
Affiliation(s)
- Eike Christian Kühn
- Charité - Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany
| | - Anna Slagman
- Charité - Universitätsmedizin Berlin, Notfallmedizin/Rettungsstellen und Chest Pain Units, Berlin, Germany
| | - Ellen C D Kühn-Heid
- Charité - Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany
| | - Julian Seelig
- Charité - Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany
| | - Christian Schwiebert
- Charité - Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany
| | - Waldemar B Minich
- Charité - Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany
| | - Christian Stoppe
- Department of Intensive Care Medicine, RWTH Aachen University, Aachen, Germany
| | - Martin Möckel
- Charité - Universitätsmedizin Berlin, Notfallmedizin/Rettungsstellen und Chest Pain Units, Berlin, Germany
| | - Lutz Schomburg
- Charité - Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany.
| |
Collapse
|
5
|
Renko K, Hoefig CS, Dupuy C, Harder L, Schwiebert C, Köhrle J, Schomburg L. A Nonradioactive DEHAL Assay for Testing Substrates, Inhibitors, and Monitoring Endogenous Activity. Endocrinology 2016; 157:4516-4525. [PMID: 27732086 DOI: 10.1210/en.2016-1549] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Iodotyrosine deiodinase (DEHAL1) is a crucial enzyme in iodine homeostasis. Unbound mono- and diiodotyrosines are indispensable byproducts of thyroid hormone biosynthesis. Their iodine needs to be recovered to avoid iodine deficiency, as observed in genetic defects in DEHAL1. Despite its importance, the enzyme is rarely studied. The deiodination process can be monitored by radioactive tracers or via techniques involving mass spectrometry. However, isotope-labeled molecules are expensive, not always commercially available, and their use is legally restricted, whereas mass spectrometry requires sophisticated, costly, and sensitive instrumentation. To circumvent these difficulties, we adapted the nonradioactive iodothyronine deiodinase assay to determine DEHAL1 activity by a colorimetric readout, based on the Sandell-Kolthoff reaction. DEHAL1 was recombinantly expressed and used to optimize the assay in microtiter format. We applied the setup to scenarios of alternative substrate screening or search for compounds potentially acting as endocrine disrupting compounds, without identifying novel readily accepted substrates or inhibitors yet. Next, the assay was adapted to ex vivo material, and activity was reliably determined from rodent kidney and other tissues. Analyzing two mouse models of hyperthyroidism, we observed a decreased renal Dehal1 activity and mRNA expression. Our results show that this nonradioactive DEHAL1 assay is suited to screen for potential endocrine disrupters and to monitor endogenous Dehal1 expression. We harmonized the assay protocols to enable iodothyronine deiodinase and DEHAL1 activity measurements from the same samples. Hereby, a more complete view on iodine metabolism by these predominant deiodinating activities can be obtained from a given sample by a similar process flow.
Collapse
Affiliation(s)
- Kostja Renko
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| | - Carolin S Hoefig
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| | - Corinne Dupuy
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| | - Lisbeth Harder
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| | - Christian Schwiebert
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| | - Josef Köhrle
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| | - Lutz Schomburg
- Institut für Experimentelle Endokrinologie (K.R., C.S.H., C.S., J.K., L.S.), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Department of Cell and Molecular Biology (C.S.H., L.H.), Karolinska Institutet, 17177 Stockholm, Sweden; Institut Gustave Roussy (C.D.), UMR 8200 CNRS "Stabilité génétique et Oncogenèse," 94805 Villejuif Cedex, France; and Center of Brain, Behavior and Metabolism/Medizinische Klinik I (L.H.), University of Lübeck, 23562 Lübeck, Germany
| |
Collapse
|
6
|
Renko K, Schäche S, Hoefig CS, Welsink T, Schwiebert C, Braun D, Becker NP, Köhrle J, Schomburg L. An Improved Nonradioactive Screening Method Identifies Genistein and Xanthohumol as Potent Inhibitors of Iodothyronine Deiodinases. Thyroid 2015; 25:962-8. [PMID: 25962824 DOI: 10.1089/thy.2015.0058] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Deiodinases (DIO1, 2, and 3) are key enzymes in thyroid hormone (TH) activation and inactivation with impact on energy metabolism, development, cell differentiation, and a number of other physiological processes. The three DIO isoenzymes thus constitute sensitive rate-limiting components within the TH axis, prone to dysregulation by endocrine disruptive compounds or disease state. In animal models and cell culture experiments, they serve as readout for local TH status and disarrangement of the hormonal axis. Furthermore, some human diseases are characterized by apparent deiodinase dysregulation (e.g., the low triiodothyronine syndrome in critical illness). Consequently, these enzymes are targets of interest for the development of pharmacological compounds with modulatory activities. Until now, the portfolio of inhibitors for these enzymes is limited. In the clinics, the DIO1-specific inhibitor propylthiouracil is in use for treatment of severe hyperthyroidism. Other well-known inhibitors (e.g., iopanoic acid or aurothioglucose) are nonselective and block all three isoenzymes. Furthermore, DIO3 was shown to be a potential oncogenic gene, which is strongly expressed in some tumors and might, in consequence, protect tumor tissue form differentiation by TH. With respect to its role in tumorigenesis, specific inhibitors of DIO3 as a potential target for anticancer drugs would be highly desirable. To this end, a flexible and convenient assay for high-throughput screening is needed. We recently described a nonradioactive screening assay, utilizing the classic Sandell-Kolthoff reaction as readout for iodide release from the substrate molecules. While we used murine liver as enzyme source, the assay was limited to murine DIO1 activity testing. Here, we describe the use of recombinant proteins as enzyme sources within the assay, expanding its suitability from murine Dio1 to human DIO1, DIO2, and DIO3. METHODS As proof-of-concept, deiodination reactions catalyzed by these recombinant enzymes were monitored with various nonradioactive substrates and confirmed by liquid chromatography-tandem mass spectrometry. RESULTS The contrast agent and known DIO inhibitor iopanoic acid was characterized as readily accepted substrate by DIO2 and Dio3. In a screening approach using established endocrine disrupting compounds, the natural food ingredient genistein was identified as a further DIO1-specific inhibitor, while xanthohumol turned out to potently block the activity of all three isoenzymes. CONCLUSIONS A rapid nonradioactive screening method based on the Sandell-Kolthoff reaction is suitable for identification of environmental, nutritive and pharmacological compounds modulating activities of human deiodinase enzymes.
Collapse
Affiliation(s)
- Kostja Renko
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Sonja Schäche
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Carolin S Hoefig
- 2 Karolinska Institutet , Department of Cellular and Molecular Biology, Stockholm, Sweden
| | - Tim Welsink
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Christian Schwiebert
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Doreen Braun
- 3 Institut für Biochemie und Molekularbiologie, Rheinische Friedrich Wilhelms-Universität Bonn, Bonn , Germany
| | - Niels-Peter Becker
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Josef Köhrle
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Lutz Schomburg
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| |
Collapse
|
7
|
Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Köhrle J, Eckstein A, Schomburg L. Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab 2013; 98:752-60. [PMID: 23264397 DOI: 10.1210/jc.2012-1771] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. Graves' orbitopathy (GO) is the main extrathyroidal manifestation of GD, potentially involving autoimmunity against the IGF1 receptor (IGF1R). OBJECTIVE We tested for autoantibodies against the IGF1R (IGF1R-Abs) in sera of GD patients and controls and elucidated their possible implication in the disease. DESIGN A diagnostic assay for IGF1R-Ab was established with recombinant human IGF1R as autoantigen. Serum samples or purified Ig preparations were analyzed for IGF1R binding and modulation of IGF1 signaling in vitro. A total of 108 consecutive GO patients represented on average by 5.4 separate serum samples per individual along with 92 healthy controls were analyzed. RESULTS IGF1R-Ab were detected in 10 serum samples from control subjects (11%) and in 60 samples (10%) from the GO patient serum bank. The positive patient samples were derived from 15 individuals yielding an IGF1R-Ab prevalence of 14% in GO. More than three consecutive samples were available from 11 of the 15 positive GO patients spanning an average disease period of 2 years. IGF1R-Ab concentrations were constantly elevated in these patients demonstrating relatively stable IGF1R-Ab expression over time. IGF1R-Ab failed to stimulate IGF1R autophosphorylation but instead inhibited IGF1-induced signaling in hepatocarcinoma HepG2 cells. Similarly, growth of MCF7 breast cancer cells was inhibited by IGF1R-Ab, supporting their classification as IGF1 antagonists. CONCLUSIONS Our data demonstrate the existence of IGF1R-Abs in humans but do not support the hypothesis that the IGF1R-Abs contribute to GO pathogenesis.
Collapse
Affiliation(s)
- Waldemar B Minich
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Suedring 10, D-13353 Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Wiedemann P, Worf M, Wiegemann HB, Egner F, Schwiebert C, Wilkesman J, Guez JS, Quintana JC, Assanza D, Suhr H. On-line and real time cell counting and viability determination for animal cell process monitoring by in situ microscopy. BMC Proc 2012; 5 Suppl 8:P77. [PMID: 22373171 PMCID: PMC3284899 DOI: 10.1186/1753-6561-5-s8-p77] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Philipp Wiedemann
- At present: School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney NSW 2052, Australia ; Mannheim University of Applied Sciences, Paul-Wittsack-Str.10, D-68163 Mannheim, Germany
| | - Markus Worf
- Mannheim University of Applied Sciences, Paul-Wittsack-Str.10, D-68163 Mannheim, Germany
| | - Hans B Wiegemann
- Mannheim University of Applied Sciences, Paul-Wittsack-Str.10, D-68163 Mannheim, Germany
| | - Florian Egner
- InVivo BioTech Services, Neuendorfstr. 24a, D-16761 Hennigsdorf, Germany
| | | | - Jeff Wilkesman
- University of Carabobo, Faculty of Sciences and Technology, Chemistry Department, Valencia, 2005, Venezuela
| | - Jean S Guez
- Laboratoire ProBioGEM, UPRES-EA 1024, Polytech-Lille / IUT A, Université des Sciences et Technologies de Lille, Avenue Paul Langevin, Villeneuve d'Ascq, F-59655, France
| | - Juan C Quintana
- Mannheim University of Applied Sciences, Paul-Wittsack-Str.10, D-68163 Mannheim, Germany
| | - Diego Assanza
- Mannheim University of Applied Sciences, Paul-Wittsack-Str.10, D-68163 Mannheim, Germany
| | - Hajo Suhr
- Mannheim University of Applied Sciences, Paul-Wittsack-Str.10, D-68163 Mannheim, Germany
| |
Collapse
|
9
|
Wiedemann P, Guez JS, Wiegemann HB, Egner F, Quintana JC, Asanza-Maldonado D, Filipaki M, Wilkesman J, Schwiebert C, Cassar JP, Dhulster P, Suhr H. In situ microscopic cytometry enables noninvasive viability assessment of animal cells by measuring entropy states. Biotechnol Bioeng 2011; 108:2884-93. [DOI: 10.1002/bit.23252] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2011] [Revised: 06/04/2011] [Accepted: 06/29/2011] [Indexed: 12/18/2022]
|
10
|
|
11
|
Schwiebert C, Lambert BG. Thromboprophylaxis for adults in hospital: Effective implementation of thromboprophylaxis strategies. BMJ 2007; 334:1128. [PMID: 17540920 PMCID: PMC1885321 DOI: 10.1136/bmj.39226.454236.3a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
Abstract
1 Cyclic AMP formation has consistently been reported to be desensitized in various tissues including heart of animal models of end-stage renal failure (ESRF). In contrast, reports on desensitization of cAMP formation in ESRF patients remain contradictory. Whether this discrepancy results from a difference between human ESRF and its animal models or from the use of circulating blood cells in the human and various solid tissues in the animal studies, remains unclear. Therefore, we performed three studies with heart and platelets of ESRF patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis and age- and gender-matched controls with normal renal function (n = 11-13 each). 2 In platelets from haemodialysis patients adenylyl cyclase activity in response to receptor-dependent and -independent agonists was reduced by approximately 30%, and this could be explained by an alteration at the level of adenylyl cyclase itself. However, no such desensitization was seen in platelets from peritoneal dialysis patients. 3 In hearts from ESRF patients undergoing haemodialysis, beta-adrenoceptor density and subtype distribution, cAMP formation in response to the beta-adrenoceptor agonist isoprenaline or various receptor-independent stimuli, were very similar to those in control patients but activity of G-protein-coupled receptor kinase was increased by approximately 20%. 4 We conclude that conflicting reports on the desensitization of cAMP formation between ESRF patients and ESRF animal models are not explained by the use of solid tissues in animal studies vs. circulating blood cells in patient studies. Rather desensitization of cAMP formation seems to be a less consistent feature of human ESRF than of its animal models.
Collapse
Affiliation(s)
- K Leineweber
- Department of Pathophysiology, University of Essen, Essen, Germany
| | | | | | | |
Collapse
|